Emmanuel Owusu Ansah

Mr. Emmanuel Owusu Ansah

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Advances in Cell and Gene Therapy
Verified
Journal Article
Open access
PDF file
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
One of the most important technologies in modern medicine is gene therapy, which allows therapeutic genes to be introduced into cells of the body. The approach involves genetics and recombinant DNA techniques that allow manipulating vectors for delivery of exogenous material to target cells. The efficacy and safety of the delivery system are a key step towards the success of gene therapy. Somatic cell gene therapy is the easiest in terms of technology and the least problematic in terms of ethics. Although genetic manipulation of germline cells at the gene level has the potential to permanently eradicate certain hereditary disorders, major ethical issues such as eugenics, enhancement, mosaicism, and the transmission of undesirable traits or side effects to patients’ descendants currently stymie its development, leaving only somatic gene therapy in the works. However, moral, social, and ethical arguments do not imply that germline gene therapy should be banned forever. This review discusses in detail the current challenges surrounding the practice of gene therapy, focusing on the moral arguments and scientific claims that affect the advancement of the technology. The review also suggests precautionary principles as a means to navigate ethical uncertainties.

31 January 2023 in Advances in Cell and Gene Therapy
Verified
Journal Article
Open access
PDF file
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
ABAndy Baah
Andy Baah
EAEmmanuel Boateng Agyenim
Emmanuel Boateng Agyenim
Immunotherapy for cancer treatment is growing at an unprecedented rate since the inception of chimeric antigen receptor T (CAR-T) cells. However, the efficacy of CAR-T cells against solid tumors is hampered by various issues, including “on-target, off-tumor toxicities,” T cell exhaustion, and immunosuppressive tumor microenvironment. To overcome these limitations, recent advances focus on optimizing CAR-T cells using vaccines to develop more effective cell immunotherapies. Here, we summarize the most recent studies on how vaccine-based CAR-T therapies are advancing the response of cancer immunotherapy as well as the current state of their clinical and preclinical development. Finally, we share perspectives on how future studies can incorporate other strategies to augment the antitumor response of vaccine-assisted CAR-T cell therapy.

2 May 2025 in Cancer Medicine
Verified
Journal Article
Open access
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
FKFoster Kyei
Foster Kyei
COCaleb Frimpong Opoku
Caleb Frimpong Opoku
ADAndrews Danquah
Andrews Danquah
KFKwadwo Fosu
Kwadwo Fosu
DADaniel Sakyi Agyirifo
Daniel Sakyi Agyirifo
Background: Blood lipids are implicated in the development of breast cancer (BC), though the genetic connection remains unclear, particularly in African populations. Observational studies on this topic are limited by confounding factors and reverse causation, potentially affecting the reliability of findings. Methods: We applied univariate and multivariable two‐sample Mendelian randomization to assess the causal association between blood lipids (total cholesterol [TC], high‐density lipoprotein [HDL], low‐density lipoprotein [LDL], and triglycerides [TG]) and BC. Summary‐level data for lipid traits were sourced from the Africa Wits‐INDEPTH partnership for Genomic Research (AWI‐Gen) ( N = 10,603 women). BC data were obtained from the largest genome‐wide association study of BC in African women, comprising 18,034 BC cases and 22,104 controls. Results: Our analysis revealed that genetically predicted TG was associated with a decreased BC risk (OR = 0.73, 95% CI = 0.56–0.95, p = 0.018. In contrast, no significant associations were found between TC, HDL, or LDL levels and BC risk: TC (OR = 1.04, 95% CI = 0.93–1.18, p = 0.467), HDL (OR = 1.29, 95% CI = 0.93–1.79, p = 0.121), and LDL (OR = 1.04, 95% CI = 0.90–1.20, p = 0.577). After adjusting for the effects of other lipid traits, the association between TG and BC was attenuated, and no associations were observed for TC, HDL, or LDL. No causal relationship was found between lipid traits and BC subtypes. Conclusions: This study provides evidence that elevated triglycerides may be associated with a reduced risk of BC, whereas no significant associations were observed for TC, HDL, or LDL. Further research is needed to better understand the underlying mechanisms and potential clinical implications of these findings.

24 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
FKFoster Kyei
Foster Kyei
COCaleb Frimpong Opoku
Caleb Frimpong Opoku
ADAndrews Danquah
Andrews Danquah
KFKwadwo Fosu
Kwadwo Fosu
DADaniel Sakyi Agyirifo
Daniel Sakyi Agyirifo
Blood lipids are associated with breast cancer. An increasing number of reports have attempted to explore the genetic connection between blood lipids and the risk of developing breast cancer. However, observational studies can be affected by confounding factors and reverse causation, which can compromise the reliability of the findings. We used univariate and multivariable two-sample mendelian randomization to explore the causal association between blood lipids and breast cancer. Summary-level data for lipid traits were obtained from the Africa Wits-INDEPTH partnership for Genomic Research (AWI-Gen) (N= 10,603, 58.5% of women). For breast cancer, we leveraged summary statistics from the most comprehensive Genome-wide Association Studies (GWAS) on breast cancer consisting of 18,034 cases and 22,104 controls of women of African ancestry. Our analysis suggests that genetically predicted triglycerides had a potential protective effect on breast carcinoma (OR = 0.73, 95% CI = 0.56, 0.95, FDR = 0.001). We found no evidence that genetically elevated levels of TC, HDL, and LDL may be associated with the risk of breast cancer TC (OR = 1.04; 95% CI, 0.93, 1.18; FDR = 0.029); HDL (OR = 1.29, 95% CI = 0.93, 1.79, FDR = 0.008); LDL (OR = 1.04, 95% CI = 0.90, 1.20, FDR = 0.036). Multivariate mendelian randomization analysis, which adjusted for the effects of TG, TC, LDL, and HDL, attenuated the observation of TG and breast cancer and also found no relationship between TC, HDL, LDL, and breast cancers. Furthermore, there was no evidence for a causal association between lipid traits and breast cancer subtypes. Our findings were robust in several sensitivity analyses. This study provides strong evidence that circulating TG may be associated with a decreased risk of breast cancer, while TC, LDL and HDL may not be related to the risk of breast cancer among African women.

31 October 2026
Verified
Preprint
Open access
PDF file
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
JYJoshua Ampofo Yentumi
Joshua Ampofo Yentumi
EKEmmanuel Yeboah Kodom
Emmanuel Yeboah Kodom
PMPrince Owusu Mensah
Prince Owusu Mensah
KFKwadwo Fosu
Kwadwo Fosu
EBEmmanuel Adu Boahen
Emmanuel Adu Boahen
Background and Aims: APOBEC-associated mutagenesis is prominent in esophageal squamous cell carcinoma (ESCC), but genomic features associated with its intertumoral variability remain incompletely characterized. We investigated genomic correlates of APOBEC-associated mutagenesis while accounting for the compositional structure of mutational signature data. Methods: Mutational signatures were analyzed in 552 ESCC tumors from eight countries. APOBEC-associated mutagenesis was quantified as SBS2 plus SBS13 using absolute mutation counts and proportional contributions. Associations with co-occurring mutational signatures, total SBS burden, recurrent driver-gene alterations, and country were evaluated using correlation, sensitivity, and multivariable analyses. Principal component and regression-model robustness were additionally assessed. Results: APOBEC burden varied markedly across tumors (median, 2,002 mutations; IQR, 987–4,346). Several associations observed using signature proportions were not maintained in absolute-count analyses: SBS1, SBS3, and SBS5 changed direction, indicating sensitivity to compositional representation. In contrast, SBS18 remained inversely associated with APOBEC-associated mutagenesis in all variable pairings examined: proportion versus proportion (Spearman ρ = −0.527), APOBEC proportion versus SBS18 absolute count (r = −0.435), and absolute count versus absolute count (Pearson r = −0.319, P = 1.59 × 10□ 1 □; Spearman ρ = −0.317). These are distinct comparisons rather than discrepant estimates. Notably, this cohort-wide relationship was primarily characterized by higher APOBEC burden in SBS18-negative than SBS18-positive tumors rather than a continuous inverse relationship among SBS18-positive tumors. The multivariable model had an in-sample R 2 of 0.400 but lower and variable 10-fold cross-validated performance (mean R 2 = 0.273). Country added little explanatory information to this model (ΔR 2 = 0.008; global P = 0.402). ZNF750-mutant tumors had higher APOBEC burden than wild-type tumors (BH-FDR q = 0.0032), although only 12 tumors carried ZNF750 alterations. Conclusion: Genomic correlates of APOBEC-associated mutagenesis in ESCC are sensitive to the representation of mutational signature activity. SBS18 showed the most consistent inverse association, whereas the ZNF750 association warrants independent validation.

25 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
BNBernard Ansong Nyarko
Bernard Ansong Nyarko
The emergence of bispecific antibodies has transformed cancer immunotherapy, highlighting increased clinical efficacy, especially in hematological malignancies. These innovative molecules uniquely target two distinct tumor antigens or separate epitopes simultaneously, demonstrating potent antitumor activity across various cancers. Despite their promise, challenges like rapid drug clearance, off-target effects, and cytokine release syndrome hinder their widespread therapeutic application. Recent engineering advancements in bispecific antibody systems aim to overcome these challenges, broadening therapeutic coverage. This review offers insights into the latest clinical and preclinical progress in bispecific immunotherapy, outlining key challenges faced by the technique, and exploring emerging strategies to address these obstacles.